TARLIGE Market Insights
Key Factors Driving TARLIGE Growth
1. Rising prevalence of neuropathic pain (large unmet need)
• TARLIGE is indicated for peripheral neuropathic pain, including diabetic peripheral neuropathy (DPN) and post-herpetic neuralgia (PHN).
• Neuropathic pain affects ~7–8% of the general population, creating a substantial treatment pool.
• Increasing diabetes prevalence globally (especially in Asia) directly expands DPN incidence, a key commercial driver.
Expanding patient pool leads to sustained volume-driven growth.
2. Differentiated mechanism with improved potency vs older gabapentinoids
• Mirogabalin binds to the α2δ subunit of voltage-gated calcium channels, reducing neuronal calcium influx and pain transmission.
• It shows higher binding affinity and longer receptor occupancy compared with older agents like pregabalin (as reported in pharmacology literature).
3. Strong clinical efficacy demonstrated in Phase III trials
• In a Phase III randomized study (n=824), mirogabalin (30 mg/day) showed statistically significant improvement in pain scores vs placebo at Week 14.
• Demonstrated efficacy across multiple neuropathic pain models (diabetic neuropathy, spinal cord injury, etc.).
• Robust clinical data underpins regulatory approvals and physician confidence, accelerating uptake.
4. Geographic expansion via licensing partnerships
• Daiichi Sankyo has expanded TARLIGE through regional licensing deals (e.g., with Menarini Group in Southeast Asia).
• Agreement covers Singapore, Malaysia, and the Philippines, with local commercialization and distribution support.
• Accelerates market penetration without heavy infrastructure investment
• Opens high-growth Asia-Pacific markets
5. Oral administration and chronic-use profile
• TARLIGE is an oral, twice-daily therapy, improving convenience and adherence vs invasive options.
• Neuropathic pain is typically chronic, requiring long-term therapy.
• Drives recurring revenue per patient
• Supports steady, predictable sales growth
6. Favorable positioning within gabapentinoid class
• Classified as a next-generation gabapentinoid, competing with pregabalin/gabapentin but offering differentiation in selectivity and pharmacokinetics.
• Potentially improved side-effect profile balance (though still includes dizziness/somnolence).
• Enables market share capture from established generics
• Premium positioning in certain markets
TARLIGE Recent Developments
• In March 2022, Daiichi Sankyo obtained approval in Japan for TARLIGE Tablets to treat neuropathic pain, based on Phase 3 data in central neuropathic pain (CNP).
“TARLIGE Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of TARLIGE for approved indication like Neuropathic pain and Postherpetic neuralgia in the 7MM. A detailed picture of TARLIGE’s existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the TARLIGE for approved indications. The TARLIGE market report provides insights about TARLIGE’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current TARLIGE performance, future market assessments inclusive of the TARLIGE market forecast analysis for approved indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of TARLIGE sales forecasts, along with factors driving its market.
TARLIGE Drug Summary
TARLIGE is an oral α2δ subunit ligand of voltage-gated calcium channels developed by Daiichi Sankyo for the treatment of peripheral neuropathic pain, including diabetic peripheral neuropathy and postherpetic neuralgia. By selectively binding to the α2δ-1 and α2δ-2 subunits, TARLIGE modulates calcium influx in hyperexcited neurons, thereby reducing the release of excitatory neurotransmitters and attenuating pain signaling. Compared to earlier agents like pregabalin, it is designed to offer sustained analgesic efficacy with improved tolerability, particularly with respect to central nervous system side effects. Administered orally, typically twice daily, TARLIGE has demonstrated significant reductions in pain scores in clinical trials and is approved in Japan and select Asian markets, though it is not yet widely approved globally. The report provides TARLIGE’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the TARLIGE Market Report
The report provides insights into:
• A comprehensive product overview including the TARLIGE MoA, description, dosage and administration, research and development activities in approved indication like Neuropathic pain and Postherpetic neuralgia.
• Elaborated details on TARLIGE regulatory milestones and other development activities have been provided in TARLIGE market report.
• The report also highlights TARLIGE‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The TARLIGE market report also covers the patents information, generic entry and impact on cost cut.
• The TARLIGE market report contains current and forecasted TARLIGE sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The TARLIGE market report also features the SWOT analysis with analyst views for TARLIGE in approved indications.
Methodology
The TARLIGE market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
TARLIGE Analytical Perspective by DelveInsight
• In-depth TARLIGE Market Assessment
This TARLIGE sales market forecast report provides a detailed market assessment of TARLIGE for approved indication like Neuropathic pain and Postherpetic neuralgia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted TARLIGE sales data uptil 2034.
• TARLIGE Clinical Assessment
The TARLIGE market report provides the clinical trials information of TARLIGE for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.
TARLIGE Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
TARLIGE Market Potential & Revenue Forecast
• Projected market size for the TARLIGE and its key indications
• Estimated TARLIGE sales potential (TARLIGE peak sales forecasts)
• TARLIGE Pricing strategies and reimbursement landscape
TARLIGE Competitive Intelligence
• Number of competing drugs in development (pipeline analysis)
• TARLIGE Market positioning compared to existing treatments
• TARLIGE Strengths & weaknesses relative to competitors
TARLIGE Regulatory & Commercial Milestones
• TARLIGE Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity
TARLIGE Clinical Differentiation
• TARLIGE Efficacy & safety advantages over existing drugs
• TARLIGE Unique selling points
TARLIGE Market Report Highlights
• In the coming years, the TARLIGE market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The TARLIGE companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TARLIGE’s dominance.
• Other emerging products for Neuropathic pain and Postherpetic neuralgia are expected to give tough market competition to TARLIGE and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TARLIGE in approved indications.
• Analyse TARLIGE cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted TARLIGE sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of TARLIGE in approved indications.
Key Questions
• What is the class of therapy, route of administration and mechanism of action of TARLIGE? How strong is TARLIGE’s clinical and commercial performance?
• What is TARLIGE’s clinical trial status in each individual indications such as Neuropathic pain and Postherpetic neuralgia and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TARLIGE Manufacturers?
• What are the key designations that have been granted to TARLIGE for approved indications? How are they going to impact TARLIGE’s penetration in various geographies?
• What is the current and forecasted TARLIGE market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of TARLIGE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to TARLIGE for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is TARLIGE? What is the duration of therapy and what are the geographical variations in cost per patient?
